Skip to main content

SYSTEMS ANALYSIS OF ADULT AND PEDIATRIC RESPONSES TO THE VSV-ZEBOV EBOLA VACCINE - Sofia ref.: 116068

Objective

The vesicular stomatitis virus (VSV)-Zaire Ebola vaccine (VSV-ZEBOV) is a recombinant vector-based vaccine in which the VSV envelope glycoprotein was replaced with the Zaire strain Ebola virus glycoprotein. Within one year of the initiation of its clinical development, the VSV-ZEBOV vaccine has demonstrated safety, immunogenicity and a remarkably high protective efficacy against Ebola Virus Disease, using a high vaccine dose (2x107 pfu) in the WHO-sponsored VSV-ZEBOV ring-vaccination trial in adults in Guinea. However, several key questions remain unanswered, including its mode of action, its correlation with protection and reactogenicity, the expected duration of protective efficacy and determinants of long-term responses, the influence of baseline immunity on vaccine “take”, and the vaccine efficacy in children - a most vulnerable population. Following the interruption of the 2014-2015 Ebola Virus Disease (EVD) outbreak, these questions, being central to the future licensing and use of VSV-ZEBOV, may not be addressed by collecting field data. The VSV-EBOPLUS project therefore proposes to use cutting-edge systems biology approaches to address these key questions, capitalizing on the unique availability of large series of extremely well defined samples from clinical vaccine studies with the VSV-ZEBOV vaccine in three different continents (Europe, Africa, US).

Specifically, the overarching objective of VSV-EBOPLUS is to comprehensively decipher the immune and molecular signatures of adult and pediatric responses elicited by VSV-ZEBOV through systems biology approaches. VSV-EBOPLUS will benefit from harmonized and standardized clinical trial protocols, in almost 1’000 adults, adolescents and children.
We propose:
1) to examine early (days 0 to 7) blood samples from 512 adults injected with graded doses (from 3x103 to 1x108 pfu) of VSV-ZEBOV;

Field of science

  • /medical and health sciences/health sciences/infectious disease/RNA virus/ebola

Call for proposal

H2020-JTI-IMI2-2015-08-single-stage
See other projects for this call

Funding Scheme

IMI2-RIA - Research and Innovation action

Coordinator

SCLAVO VACCINES ASSOCIATION
Address
Piazza La Lizza 7
53100 Siena
Italy
Activity type
Research Organisations
EU contribution
€ 1 625 000

Participants (10)

UNIVERSITE DE GENEVE
Switzerland
EU contribution
€ 0
Address
Rue Du General Dufour 24
1211 Geneve
Activity type
Higher or Secondary Education Establishments
MERCK SHARP & DOHME CORP
United States
EU contribution
€ 0
Address
One Merck Drive
08889 Whitehouse Station Nj
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
GOETEBORGS UNIVERSITET
Sweden
EU contribution
€ 1 698 750
Address
Vasaparken
405 30 Goeteborg
Activity type
Higher or Secondary Education Establishments
UNIVERSITA DEGLI STUDI DI SIENA
Italy
EU contribution
€ 1 645 000
Address
Via Banchi Di Sotto 55
53100 Siena
Activity type
Higher or Secondary Education Establishments
ACADEMISCH ZIEKENHUIS LEIDEN
Netherlands
EU contribution
€ 1 696 875
Address
Albinusdreef 2
2333 ZA Leiden
Activity type
Higher or Secondary Education Establishments
MICROBIOTEC SRL
Italy
EU contribution
€ 485 000
Address
Via Delle Vigne 12
53035 Monteriggioni
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Germany
EU contribution
€ 395 625
Address
Geschwister-scholl-platz
72074 Tuebingen
Activity type
Higher or Secondary Education Establishments
UNIVERSIDADE DE SAO PAULO
Brazil
EU contribution
€ 306 250
Address
Rua Da Reitoria 109 Butanta
05508 900 Sao Paulo Sp
Activity type
Higher or Secondary Education Establishments
EIDGENOSSISCHES DEPARTEMENT FUR VERTEIDIGUNG, BEVOLKERUNGSSCHUTZ UND SPORT
Switzerland
EU contribution
€ 0
Address
Bundeshaus Ost
CH-3003 Bern
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Centre de Recherches Medicales de Lambaréné
Gabon
EU contribution
€ 701 250
Address
Na
118 Lambaréné
Activity type
Research Organisations